Cubist Pharmaceuticals Inc

Cubist Pharmaceuticals — Q1 2005 Earnings Presentation

21 slides from Cubist Pharmaceuticals's earnings presentation, Apr 22, 2005

  1. Slide 1: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  2. Slide 2: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  3. Slide 3: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  4. Slide 4: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  5. Slide 5: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  6. Slide 6: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  7. Slide 7: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  8. Slide 8: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  9. Slide 9: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  10. Slide 10: Cubicin Commercialization: Manufacturing Capacity

    Cubicin® Commercialization CUBIST Manufacturing Capacity " Ee ee jae zal PO ETTITY oow | 2004 1Q05

  11. Slide 11: Cubicin International Commercialization

    Cubicin® International Commercialization [ny Marketing Rights . © Oryx Pharmaceuticals = Canada + Chiron ~ Western and Eastern EU, Australia, New Zealand, India, and certain Central ‘American, South American and Middle Eastern Countries + Medison Pharma, Ltd. ~ Israel + TTY Biopharm Company — Taiwan

  12. Slide 12: Pipeline: Strategic Focus

    Pipeline CUBIST Strategic Focus Ese Serious and Life-Threatening Infections -Lipo 2 Research

  13. Slide 13: Research: 2nd Generation Lipopeptide with lung activity

    — Research 2nd Generation Lipopeptide with lung activity Log (CFUIm)) CUBIST Pulmonary reduction of burden of S. pneumoniae Infection in Mice 4.1 log reduction 4 6.1 log reduction 2 % s 10 mgikg 100 mgkg 100 mgkg Saline Daptomycin Compound x *Compound X shows reduced pulmonary bacterial burden by 5

  14. Slide 14: Summary Statement of Operations

    Summary Statement of Operations Cubicin® revenues, net Total revenues Cost of product revenues Other operating expenses ‘Operating loss Other expenses Net loss EPS In thousands except per share data ‘Three months ended March 31, 2005 = 2004 ‘(Unaueited) $ 20889 6281 23.682 8.471 6925 2,425 28,050 26

  15. Slide 15: Daily Cubicin Net Product Sales Per Shipping Day

    eee Dollars in thousands: = 8 a2 04 a Daily Cubicin® Net Product Sales Efpiay Per Shipping Day (Unaudited)

  16. Slide 16: Account Ordering Trends

    Account Ordering Trends 70 CUBIST 6 LEFT ye 3 E f_ fe B = < oe : gx» se - mnie ae A ae ee Note: Calculations include only those accounts that order in each given month: ‘Source: Updated Order Summary (through 3/31/05)

  17. Slide 17: Cubicin Repeat Accounts

    Cubicin® Repeat Accounts cubs + Vial orders continue to trend upward = On average - 125 repeat accounts ordering per day - On average — 7 new accounts ordering per day ot tetnmnnee Qedincinn nae Fons t6 Fo Bene —Repeat Customers —30 day Moving Average (Repeat Customers ‘Source: Cubiet Order Summary:

  18. Slide 18: Penetration and Formulary Approvals by Type of Account

    Penetration and Formulary Approvals by Type of Account Account Potential Customers % of Potential % Formulary Type | Customers | Ordering | Customers Approval Ordering A 318 295 93% 72% B 546 454 83% 58% c 868 513 59% Not Tracked DIO 17,588 2,254 13% Not Tracked Total 19,290 3516 18% Not Tracked Sou

  19. Slide 19: 2005 Cubicin Guidance

    2005 Cubicin® Guidance + CUBICIN revenue range: + Cost of goods sold range: + Operating expense range: — Research and development = Sales and marketing - G&A + Net interest estimate: CUBIST $110 - $120 million 32.8% - 30.0% $ 2-64 million $ 43- 45 million $ 19 = 20 million $114 - 119 million $7 mill

  20. Slide 20: 2005 Milestones

    2005 Milestones CUBIST + Add supply chain capacity in 1HOS {@ ACS Dobfar, second API manufacturing site approved by FDA sNDA (CBE-30) filed for fillfinish at Cardinal Health's Biotechnology and Sterile Life Sciences Facility + Expanded Sales Force [Completed 1005 + CORE abstracts/publication submiss

  21. Slide 21: Searchable text section of graphics shown above

    Searchable text section of graphics shown above Ser ious Infections. [LOGO] Serious Business. Statements made during this presentation that are not historical fact may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that

Cubist Pharmaceuticals — Q1 2005 Earnings Presentation on 6ix